{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0002524\nAge: 74\nGender: Female\nSample ID: P-0002524-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nEGFR c.2573T>G (p.L858R) - in 59.00% of 668 reads\nKRAS c.183A>C (p.Q61H) - in 4.00% of 327 reads\nKRAS c.64C>A (p.Q22K) - in 3.00% of 344 reads\nPTPRT c.577C>T (p.P193S) - in 12.00% of 287 reads\nTP53 c.488A>G (p.Y163C) - in 25.00% of 252 reads\nCNA Data:\nEGFR - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Erlotinib or Osimertinib\",\n    \"Prior Treatment or Resistance Status\": \"EGFR L858R mutation, EGFR amplification\",\n    \"Genomic Features\": \"EGFR c.2573T>G (p.L858R) mutation, EGFR high level amplification\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202515s017lbl.pdf\"\n  }\n}"
}